After serial failures with tau antibodies for Alzheimer’s, BMS’ expanded deal with Prothena signals its growing confidence in PRX005, a new molecule targeting a different region on the toxic protein.
Bristol Myers Squibb has opted to buy the global rights to Prothena’s anti-tau Alzheimer’s candidate PRX005, paying $55m to expand an existing US-only deal.
There have been scores of failed tau-targeting candidates over the last two decades, but enhanced understanding of how to target the toxic protein, along with the US approval of Eisai/Biogen’s amyloid-targeting Alzheimer’s drug Leqembi
Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.
BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.
GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.
ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.
A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.
